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1 Novo Nordisk Research Center, Seattle, WA, USA, 2 Pacific Northwest Diabetes Research Institute, Seattle, WA, USA
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) target-
ing of self-antigens that can lead to tissue destruction in autoimmune settings, including 
type 1 diabetes (T1D). Autoimmunity is caused in part by an imbalance between Teff 
and Tregs. Early attempts to treat with immunosuppressive agents have led to serious 
side effects, thus requiring a more targeted approach. Low-dose IL-2 (LD IL-2) can 
provide immunoregulation with few side effects by preferentially acting on Tregs to drive 
tolerance. The concept of LD IL-2 as a therapeutic approach is supported by data in 
mouse models where autoimmunity is cured and further strengthened by success in 
human clinical studies in hepatitis C virus-induced vasculitis, chronic graft-versus-host 
disease, and Alopecia areata. Treatment will require identification of a safe therapeutic 
window, which is a difficult task given that patients are reported to have deficient or 
defective IL-2 production or signaling and have experienced mild activation of NK cells 
and eosinophils with LD IL-2 therapy. In T1D, an LD IL-2 clinical trial concluded that Tregs 
can be safely expanded in humans; however, the study was not designed to address 
efficacy. Antigen-specific therapies have also aimed at regulation of the autoimmune 
response but have been filled with disappointment despite an extensive list of diverse 
islet antigens tested in humans. This approach could be enhanced through the addition 
of LD IL-2 to the antigenic treatment regimen to improve the frequency and function of 
antigen-specific Tregs, without global immunosuppression. Here, we will discuss the use 
of LD IL-2 and islet antigen to enhance antigen-specific Tregs in T1D and focus on what 
is known about their immunological impact, their safety, and potential efficacy, and need 
for better methods to identify therapeutic effectiveness.
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iNTRODUCTiON
Since the discovery of the 15.5 kDa protein Interleukin-2 (IL-2) numerous preclinical, clinical, and 
mechanistic studies have provided basic insights into its role in immunity (1–3). In 1998, Proleukin® 
(Aldesleukin, human recombinant IL-2) was approved by the FDA for use at a sustained high dose 
in patients with metastatic renal cell carcinoma (MRCC) or metastatic melanoma (MM) (4, 5). The 
high doses and repeated administration were based on the protein’s short half-life (6). However, only 
a subset of treated patients exhibited improved outcome and the high-dose (HD) IL-2 treatment 
came with severe side effects (7, 8). Despite its long history, it is not understood why some patients 
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respond to the therapy while most do not (7, 8). Subsequently, 
IL-2 has been pursued in different indications, using low doses 
which resulted in minimal side effects (8, 9). Studies have reported 
success of low-dose (LD) human recombinant IL-2 (LD IL-2) 
therapy in animal models of autoimmune pathology (10–14). 
In this context, the advantageous function of IL-2 appears to be 
expansion of antigen-specific regulatory T cells (Tregs) curing a 
number of autoimmune conditions in mice (10–14). This poten-
tial is further strengthened by success in human clinical studies in 
hepatitis C virus (HCV) induced vasculitis, chronic graft-versus-
host disease (GVHD), T1D, systemic lupus erythematosus (SLE), 
and Alopecia areata (15–21).
Antigen-specific therapies in T1D aimed at regulation of the 
autoimmune response by tolerance induction have been filled with 
disappointments despite an extensive number of human trials. 
These trials tested primarily three autoantigens: insulin, glutamic 
acid decarboxylase (GAD), and heat shock protein 60 (Hsp60), 
either intact or components thereof (22–25). The combination 
of LD IL-2 together with an antigen-based therapy specific to a 
target organ or tissue may be a means to provide strong immu-
nomodulation without general immunosuppression. The effect 
would likely involve the enhancement of antigen-specific Tregs 
in both their number and activity. The major question remains 
whether a proper dosing strategy for LD IL-2 as an induction 
agent can be identified that will include both an acceptable safety 
profile and measure of efficacy. A further consideration is how to 
best identify and predict efficacy of LD IL-2 therapy either with 
or without an antigen therapy. A dosing strategy for an antigen-
based therapy is also required and the diversity of patients and 
the manifestation of disease must also be better understood. 
Currently, the common study end-points in intervention trials for 
T1D with LD IL-2 administration are clinical remission defined 
by preservation of C-peptide, decreased level of HbA1c, decreased 
insulin requirement, normal blood glucose, absence or reduced 
adverse events including vascular leak syndrome (VLS), serious 
infections, and allergic reactions, increased counts of eosinophils 
and neutrophils, and expansion of Tregs (15, 16). T1D is a 
complex autoimmune disease that presents in younger children 
in a faster, more aggressive onset, and progression. Intervention 
trials are mostly initiated at a later stage of disease development, 
when β-cell loss is well established and the intervention therapy 
is less likely to improve disease outcome or progression (26). 
Being able to conclude confidently that LD IL-2 administration 
is efficacious and safe for patients with T1D, we need reliable and 
robust immune biomarkers and assays that (1) will help to stratify 
the study population and (2) predict at which stage of disease 
progression the administration of LD IL-2 alone or in combina-
tion with an antigen-specific therapy will be efficacious in curing 
or preventing T1D.
iL-2 AND iL-2 ReCePTOR
IL-2 was the first cloned interleukin in 1983, and it is arguably 
the most investigated interleukin with a wide role in regulation 
of the immune system (27, 28). Initially, IL-2 was described as a 
T-cell growth factor with production mainly driven by antigen-
activated CD4+ T cells following the engagement of the T-cell 
receptor (TCR) and costimulation through CD28 (1, 28, 29). 
IL-2 is also produced, at a lower level, by activated CD8+ T cells, 
dendritic cells, natural killer (NK) cells, and NKT cells (28, 30). 
After its secretion, IL-2 binds to its high affinity IL-2 receptor 
(IL-2R) consisting of three individual subunits IL-2Rα (CD25), 
IL-2Rβ (CD122), and IL-2Rγ (CD132) (31). IL-2 has low bind-
ing affinity to IL-2Rα and intermediate affinity to the dimeric 
complex IL-2Rβ/γ (31). Analysis of the crystal structure of this 
quaternary complex showed that IL-2 binds first to IL-2Rα and 
then to the two subunits IL-2Rβ and IL-2Rγ (32–34). Naïve CD4+ 
T cells and immature and mature B-cells express almost none of 
the three subunits of IL-2R on their surface (28). Naïve CD8+ T 
cells, memory CD4+ and CD8+ T cells, NK, and NKT cells show 
low expression of the IL-2Rβ and IL-2Rγ subunits (28). Cells that 
express higher levels of the dimeric complex IL-2Rβ/γ are more 
sensitive to HD IL-2 administration resulting in severe effects 
including VLS (28). On the cell surface of Tregs, high expression 
of the tri-complex IL-2Rα/β/γ can be detected and contributes to 
higher sensitivity of these cells to LD IL-2 (28). Independently 
of the existence of IL-2Rα, both IL-2Rβ and IL-2Rγ can induce 
fully competent IL-2 signaling resulting in activation of phospho-
inositol 3-kinase (PI 3-K)/AKT, Ras-MAP kinase, and JAK-STAT 
pathways for mediating cell growth, survival, death, and differen-
tiation (2, 28, 32, 35).
The IL-2 signal plays a major role in the homeostasis and 
activation of CD4+CD25+Foxp3+ Tregs (31). The quaternary 
complex consisting of IL-2 and IL-2Rα/β/γ induces the phos-
phorylation of STAT5, resulting in increased expression of CD25 
and Foxp3 on Tregs and activation of their suppressive activity 
(28, 36). In vivo as well as in vitro experiments have elucidated 
the roles of IL-2 and IL-2R in the homeostasis and activation 
of Tregs (1, 37–39) (Figure 1). Deficiency in signaling through 
IL-2, IL-2Rα, or IL-2Rβ, or STAT5 results in lethal autoimmunity, 
dysregulation and decline of Treg production, and uncontrolled 
Teff activity (37–40) leading to an imbalance between Tregs and 
Teff cells (Figure 1). Patients with autoimmune disease includ-
ing SLE, T1D, or rheumatoid arthritis have defective expression 
and regulation of IL-2 and IL-2R resulting in dysregulated Treg 
function and impaired downstream signaling (41–45). Data from 
genome-wide association studies have shown that the IL-2 locus 
Idd3 in non-obese diabetic (NOD) mice and 4q27 in humans 
are risk factors for susceptibility to development of T1D (40, 
46). Boosting with exogenous IL-2 in IL-2-deficient mice led to 
restoration of the impaired Treg population and also prevented 
disease development (10–12, 14, 47). It is unclear if clinical trials 
have seen a similar successful remission rate with the application 
of IL-2 in patients with a potential risk for the IL-2-, IL-2R-, or 
Treg-deficiency since these were not tested (15–21). In the case 
of IL-2R deficiency, there would likely be no therapeutic effect 
with LD IL-2.
MOviNG FROM HD iL-2 iN CANCeR TO 
LD iL-2 FOR AUTOiMMUNe DiSeASeS
Proleukin® was considered an attractive immunotherapy for 
patients with MRCC or MM. The first trial to use HD IL-2 
FiGURe 1 | increased expansion and activity of Teff cells with reduced Treg number and function in autoimmune diseases like T1D are shown. This 
figure simplifies a complex situation in autoimmune disease. There is a balance required for tolerance to be maintained while allowing for efficient response to 
pathogen or other challenges. The main insight to this balance comes from lack of Foxp3 in humans and mice where the lack of Tregs leads to unchecked 
destruction and death by Teff cells.
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was reported in 1985 by Rosenberg et  al. (48). Seven percent 
of patients showed complete clinical remission from MM and 
MRCC with 13% showing partial regression after administra-
tion with HD IL-2 (7). The most life-threatening adverse effect 
with HD IL-2 is VLS. This acute toxicity is mediated primarily 
by neutrophils and eosinophils leading to higher expression of 
reactive oxygen, proteases, and proinflammatory cytokines (49). 
Modified versions of IL-2 and IL-2 complexes are currently under 
development with the goal to extend the half-life of IL-2, reduce 
the dose of IL-2, and fine-tune the activity of IL-2 on specific 
target cells with the aim of reducing or eliminating severe side 
effects (50, 51). The vision is for an engineered “superkine” IL-2 
that will only activate Tregs without activating Teff, NK cells, or 
eosinophils (50, 51). This is a promising direction that needs to 
be strongly pursued, but FDA-approved Proleukin® is available 
now. Previous studies have shown that the administration of 
HD IL-2 can expand the population of Tregs in cancer patients. 
Subsequently, a lower dose of Proleukin® was tested in patients 
with autoimmune disease aiming to restore the defect in Tregs 
(17). The first clinical trial reporting successful induction of 
Tregs, safety, and clinical efficacy with LD IL-2 involved patients 
with HCV (17). In a preclinical study, Churlaud et al. revealed 
that long-term administration of LD IL-2 to NOD mice neither 
induced systemic toxicity nor impaired the immune response 
(52). Nevertheless, LD IL-2 is linked to increased eosinophil and 
neutrophil numbers in clinical trials (15, 20, 53). Further dosing 
studies are required to identify the optimal dose that provides 
efficacy and safety in humans while limiting these side effects. 
This is a complex issue, given patient heterogeneity and differ-
ences in IL-2 signaling among individuals (50, 51).
eFFeCTive TReATMeNT OF 
AUTOiMMUNe DiSeASe iN MURiNe 
MODeLS wiTH LD iL-2
In a study by Grinberg-Bleyer et al., the administration of LD IL-2 
(25,000 IU) for five consecutive days resulted in remission of dis-
ease and normal blood glucose in 60% of treated NOD mice (10). 
The LD IL-2 induced a 1.5-fold increase in the number of Tregs 
in the pancreas of prediabetic mice as well as increased expression 
of CD25, Foxp3, CTLA-4, ICOS, and GITR which are important 
for Treg function have been found to be reduced in children with 
T1D (54). In a disease prevention study, NOD mice treated with 
low dose of IL-2 in the form of a IL-2/anti-IL-2 mAb complex led 
to a small increase in Treg cell percentage and a positive correla-
tion with CD25 and Bcl-2 expression compared to control mice 
(14). No difference in expression of NK cells was reported.
Successful protection against islet β-cell destruction has also 
been observed with a combination therapy of rapamycin and LD 
IL-2 (13). Treatment with human recombinant IL-2 alone (4 ng/
day) in NOD mice between the ages of 10–25  weeks did not 
prevent disease development while a dose-dependent decline in 
diabetes incidence in NOD mice treated with rapamycin alone 
(0.1 and 1.0  mg/kg/day) at the age of 10–33  weeks was seen. 
However, a synergistic effect was achieved using combination 
therapy with rapamycin plus human recombinant IL-2 that sig-
nificantly decreased diabetes incidence in NOD mice compared 
to the vehicle-treated group. Disease prevention was maintained 
even after withdrawal of the combination therapy (13). Results 
like these encouraged the idea of using combinations to treat 
T1D, realizing the difficulty inherent in translating mouse studies 
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to humans. We propose a LD IL-2 and antigen-specific therapy 
combination to induce immune tolerance occurring most likely 
through increase number and activity of antigen-specific Tregs. 
For example, a combination therapy of LD IL-2 with rapamycin 
has been shown to prevent allogeneic skin graft rejection in mice 
presumably through an increase in Treg production and decline 
of Teff cells detected in grafted mice (12). However, monotherapy 
with LD IL-2 (50,000  IU) or rapamycin did not prevent rejec-
tion (12). While rapamycin had adverse events in humans when 
tested in combination with LD IL-2, we propose the use of LD 
IL-2 in combination with an autoantigen like insulin or an insulin 
peptide (discussed below) be used as potential safe and effica-
cious therapy to prevent or reverse disease, in part by remedying 
the dysregulation of Treg and Teff cells, without impairing the 
immune response (53). The promising results in preclinical stud-
ies led to the use of LD IL-2 in the clinic. Since the therapeutic 
window of human recombinant IL-2 is narrow, further careful 
investigations are needed to determine a safe treatment strategy 
for LD IL-2. Evidence of the therapeutic potential of LD IL-2 in 
other immune diseases is compelling.
CLiNiCAL APPLiCATiON OF LD iL-2 iN 
PATieNTS wiTH HCv
In a single-center, open-label, prospective phase 1/2 trial, Saadoun 
et al. investigated the efficacy and safety of low-dose Proleukin® in 
HCV-infected patients with mixed cryoglobulinemia who were 
refractory to previous antiviral therapies (17). Subcutaneous 
(s.c.) administration of LD IL-2 (1.5 million IU/day) was admin-
istered in four courses. First, patients received a 5-day course of 
1.5 million IU of LD IL-2 followed by three 5-day courses of 3 
million IU/day at weeks 3, 6, and 9. Clinical improvement of HCV 
was seen in eight out of 10 patients after receiving LD IL-2. They 
did detect an increase in the percentage of CD4+, FOXP3+CD25 
high (17). In a recent audit of VASCU-IL-2 trial, errors lead to a 
correction and update of results that include loss of significance 
for both the decrease of cryoglobulinemia and the increase of 
C4 levels during administration of LD IL-2 in original report. 
In addition, a grade 2 serious adverse event was discovered and 
included in the correction (17).
In another study with patients coinfected with HIV/HCV 
administration of lower dose human recombinant IL-2 led to 
expansion and activation of Tregs, improvement of liver function, 
and reduction of inflammation (55, 56). These data indicate a 
promising new treatment option for patients with HCV but fur-
ther testing in a larger number of patients is needed (17, 55, 56). 
Additionally, a dose must be identified that remains efficacious 
with minimal or no increase in eosinophils and NK cells. Future 
studies should also identify long-term efficacy and identify any 
additional adverse events for this indication (17).
eFFiCACY OF LD iL-2 iN PATieNTS  
wiTH GvHD
Administration of lower dose Proleukin® has been shown 
to improve the ratio between Tregs and Teff and to induce 
proliferation of peripheral Tregs while enhancing their resistance 
to apoptosis in patients with GVHD (19). In a phase 1 study, 
a dose-tolerance escalation trial was conducted for LD IL-2 in 
GVHD patients’ refractory to glucocorticoids (20). For 8 weeks, 
a total of 29 patients received daily s.c. administration of LD 
IL-2. The patients were divided into three different dose levels 
(0.3 × 106, 1 × 106, or 3 × 106 IU/m2 of body-surface area) (20). 
After a 4-week break in treatment, follow-up treatment was initi-
ated only in responders. The dose of 1 × 106 IU/m2 per day was the 
highest tolerated concentration. The higher dose of 3 × 106 IU/m2 
induced side effects that included fever, malaise, and arthralgia. 
In summary, there was no evidence of GVHD flare with LD IL-2 
treatment, and 12 of 23 patients with GVHD showed partial 
response during the 8-week treatment period, with lower risk 
for erythema, higher joint mobility and gait, and improvement 
of liver function. One patient showed complete remission after 
14 months even with discontinuation of both immunosuppres-
sant and LD IL-2 (20). Additionally, two patients did not require 
glucocorticoid therapy after 30 and 36 months. After 4 weeks of 
LD IL-2 administration, the proportion of Tregs increased signifi-
cantly to more than eight times the baseline level (20). However, 
the discontinuation of LD IL-2 led to a decline of Treg counts 
but remained higher than baseline. The median ratio of Treg:Teff 
was fivefold higher than the baseline level after 4 weeks LD IL-2 
therapy. NK cells also increased during the treatment window 
but decreased after LD IL-2 was withdrawn. Similarly, LD IL-2 
administration has been tested in patients receiving hematopoi-
etic stem cell transplantation in order to prevent GVHD (57). 
No adverse events of grade 3 or 4 nor any induction of GVHD 
were reported. In addition to an expansion of Treg levels, viral 
infections were actually reduced in the LD IL-2 treated group 
compared to the control group (57). These data demonstrated 
that administration of LD IL2 was well tolerated and effective 
in preventing disease progression in patients with alloimmune 
disease. In the future, exciting clinical trials are expected for the 
clinical implication of LD IL-2 in GVHD (20, 57).
LD iL-2 THeRAPY iN ALOPeCiA AReATA
Alopecia areata is a T-cell-mediated disease involving the recogni-
tion of follicular autoantigens, resulting in inflammation-induced 
hair loss (58, 59). Patients with alopecia areata have a significantly 
higher number of Th17 cells but decreased Tregs in the peripheral 
blood compared to healthy controls (60). In a prospective, open 
pilot study, five patients with severe Alopecia areata received s.c. 
administration of LD IL-2 (1.5 million IU/day) for 5 days, and at 
weeks 3, 6, and 9 further 5-day courses of higher dose of 3 mil-
lion IU/day of IL-2 (21). Using severity scoring scale for Alopecia 
areata, patients treated with LD IL-2 experienced a disease score 
improvement from 82 to 69. Furthermore, four out of five patients 
showed partial regrowth of scalp hair and an increased level of 
Tregs; however, this result was not statistically significant (60). 
Also, the number of recruited patients in this pilot study was very 
small, but the data offer promising results for a new treatment 
option in Alopecia areata.
Altogether, recent published clinical trials with LD IL-2 
reported mild degrees of efficacy and safety and some evidence of 
FiGURe 2 | induction followed by maintenance of self-tolerance requires a balance between Treg and Teff to prevent or cure type 1 diabetes.  
The ability of LD IL-2 to improve the number and function of Tregs to restrain auto-reactive Teffs has shown promise in humans. However, human and T1D disease 
heterogeneity require better measures of Treg function and overall efficacy because this therapy may be more efficacious in a subset of individuals with T1D. The 
overall enhancement of Treg function will likely further benefit from targeted enhancement of Treg specific for islet antigens like insulin or insulin peptide. Antigen-
specific therapy requires more early validation in humans with similar need of immune biomarkers that can access therapeutic effect or patient stratification. The 
measure of therapeutic effect is paramount for potential testing of both LD IL-2 and antigen-specific therapy in combination.
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restoration of impaired Treg function (17, 19–21, 57). However, 
it is still not clear whether the promise of LD IL-2 for treatment 
of autoimmune diseases will be met. Nevertheless, we need to 
continue progress by focusing next on the identification of the 
therapeutic window of IL-2, which is no easy task given the het-
erogeneity inherent to human populations (61, 62). Development 
of good and reliable immune biomarkers and assays for predic-
tion of the clinical efficacy and possible long-term adverse effects 
with LD IL-2 as well as a better understanding of the mechanism 
of action in heterogeneous responders are therefore urgently 
needed (see below and Figure 2).
LD iL-2 AS A NOveL THeRAPY FOR 
PATieNT wiTH T1D
The efficacy of LD IL-2 was tested for the first time in a phase 1/2, 
double-blind, randomized, placebo-controlled trial with 24 T1D 
patients who were in an age range of 18–55 years and positive 
for at least one diabetes-associated autoantibody (15). The groups 
consisted of six patients each receiving either placebo, LD IL-2 at 
0.33 MIU/day, LD-IL-2 at 1 MIU/day, or LD IL-2 at 3 MIU/day, 
for 5 days with a 60-day follow-up period. Overall, all patients 
appeared to tolerate the LD IL-2 well. The level of fasting C-peptide, 
incremental area under the curve (iAUC) plasma C-peptide, 
fasting plasma glucose, HbA1c, and insulin requirements were 
similar between treated groups. Significant incremental maxi-
mum effect and iAUC of Treg proportion were observed during 
the treatment period. A minimal but non-significant change 
in Teff and NK cells was also reported. Follow-up experiments 
tested increasing doses of LD IL-2 in an effort to determine a 
dose that would stimulate human Tregs without affecting other 
cells associated with the IL-2R (16, 62). Higher percentage of 
Tregs and enhanced levels of activation markers including CD25, 
GITR, CTLA-4, and basal pSTAT5 were detected and the data 
revealed that Tregs were 20-fold more sensitive to IL-2 than NK 
cells and memory T cells (16). In in vitro experiments, investiga-
tors found that increased expression of CD25 alone in activated 
CD4+ T cells did not affect the high sensitivity of Tregs to IL-2 
(62). Furthermore, this study reported that the EC50 level for IL-2 
induction of STAT5 phosphorylation between T1D patients and 
healthy subjects was similar, and there is a response gap between 
Tregs and CD4+ memory T cells in patients with T1D, which may 
be important in determining an effective therapeutic window for 
LD IL-2 for treatment of T1D (62). Additional, broader effects 
not directed at Tregs were also found and warrant further study 
and an improved understanding of Treg/Th17 balance (63) An 
important concern remains the potential unwanted activation 
of NK cells and eosinophils with LD IL-2. Overall, these studies 
pave the way for LD IL-2 therapy in T1D to enhance antigen- 
specific Tregs.
January 2016 | Volume 6 | Article 6516
Pham et al. Antigen-Specific Therapy with LD IL-2
Frontiers in Immunology | www.frontiersin.org
ANTiGeN-SPeCiFiC THeRAPY iN 
PATieNTS wiTH T1D
Autoantigens have been of interest in T1D for treating the 
autoimmune component of the disease coinciding with the dis-
covery of autoantibodies and T cells specific for GAD (GAD65), 
insulin, insulinoma-associated protein 2 (IA2), islet-specific 
glucose-6-phosphatase catalytic subunit related protein (IGRP), 
zinc transporter 8 (ZnT8), and others (64). Many of these 
autoantigens were identified as targets of the damaging immune 
response in the pancreas and then tested in preclinical models in 
a setting aimed at the induction of immunological tolerance to 
the autoantigens. Promising results seen in previous preclinical 
studies for preventing or reversal of T1D led to clinical trials 
(24, 65–69). Given the evidence in preclinical models, it is of 
great interest to test the efficacy of antigen-specific therapy in 
combination with LD IL-2. Unfortunately, most clinical trials 
testing autoantigens to prevent or cure T1D were disappointing. 
The trials focused primarily on three autoantigens insulin, GAD, 
and Hsp60, administered as intact protein or peptide derived 
from the autoantigen with very different routes of administra-
tion. In the case of insulin, the results have not indicated any 
significant effect despite attempts at the delivery of insulin orally, 
intranasally, and subcutaneously (24, 67, 68). A closer inspec-
tion of these disappointing results is important given the lack 
of information on optimal dosing strategy or route used in each 
trial. In the case of oral antigen administration, doses required 
in mice are larger than any used in clinical trial, and it is unclear 
how much insulin would remain undigested by the time it 
reached the small intestine without any encapsulation (70). The 
hsp60 peptide Diapep277 had marginal reduction in C-peptide 
and GAD65 in alum slowed beta cell loss, but the results were not 
repeated in Phase III (71–75). However, valuable information 
was obtained from these studies, including evidence of increased 
IL-10 and reduced T cell responses in patients treated with 
Hsp60, while patients treated with GAD alum had increased 
Tregs, T-cell proliferation, and inflammatory cytokines (76). It 
is imperative that we find appropriate immune biomarkers of 
response to antigenic therapy that measure immune responses 
to therapeutic self-antigens early during treatment (briefly 
mentioned below). The most promising antigen candidate for 
this therapy is insulin or an insulin-derived peptide. The basic 
idea would be to induce an infectious tolerance with the insulin-
derived autoantigen that would provide protection from immune 
responses against other known T1D islet antigens. For example, 
it would be highly important if the number and function of Tregs 
specific for insulin could accurately and reliably be measured 
during and after treatment with the self-antigen. We believe that 
antigen therapy may not work alone but is better suited for use 
in combination with LD IL-2 or another induction agent and the 
antigen will likely have to be given continuously or as booster. 
Further studies are needed in both mice and human to validate 
the proposed combination in T1D. In addition, we must seri-
ously consider the use of combination therapies that also work 
on metabolic dysregulation in the islets since there are likely 
components of T1D that are not immune related that could be 
of greater benefit if combined in the future (26). Biomarkers will 
have to be developed to better understand the natural history of 
T1D and that will inform clinical trials of the action or efficacy 
of a particular therapy.
TO MOve THe FieLD FORwARD: 
ReLiABLe AND ROBUST iMMUNe 
BiOMARKeRS
The path toward a cure in T1D has been filled with many challenges 
(25, 64, 65). Many clinical trials have tested potential therapies for 
a cure or delay in the onset of T1D (24, 65–73, 77). However, the 
promising results seen in the NOD mouse model have, thus far, 
not translated to the clinic (24, 65–73). Unfortunately, reasons 
for failures are poorly understood in large part due to our lack 
of understanding about the cause or natural history of T1D and 
the difficulty of enrollment of younger age groups, where therapy 
may be more efficacious, but ethical and regulatory body restric-
tions limit or prevent participation.
In clinical trials, the C-peptide level has been relied on as 
a clinical endpoint together with blood glucose, HbA1c, and 
insulin requirement. C-peptide provides information about β-cell 
function and insulin production, but it is heterogeneous among 
patients depending on age, stage of diagnosis, disease progress, 
and sex with a slow decline in adults compared to children (26, 
78, 79). For this reason, a more sensitive immune biomarker is 
required that could also allow for stratification of patients enrolling 
in clinical trials. From previous trials, it has been reported that 
higher C-peptide level is associated with lower HbA1c, reduced 
insulin requirement, reduced hypoglycemic events, and reduced 
retinopathy (80). Better stratification of patients would require 
immune biomarkers that could follow TID natural history (81, 82). 
Additional surrogate markers of β cells are needed to identify cell 
destruction, stress, or metabolic imbalance not limited to immune 
system parameters. Examples include miRNA, methods to meas-
ure pancreas size, or composition, and non-invasive imaging (26).
T1D is in part an immune-mediated and antigen-driven 
disease resulting in an imbalance between Tregs and Teff, we 
therefore need validated immune biomarkers and assays that can 
give us clear answers (1) about the functionality and quantity of 
islet antigen-specific T cells; (2) whether the intervention therapy 
will enhance Tregs; and (3) whether the restoration of antigen-
specific or polyclonal Treg number and function will correlate 
positively with the pancreatic islet function.
Previous studies have reported that the disease development 
of T1D is associated with the presence of a specific signature 
of cytokines and adhesion molecules that can be captured by 
ELISA or Luminex assays (83). However, the organ that suffers 
most during the disease development of T1D is the pancreas; 
therefore, we need robust methods that can measure the activity 
and infiltration of immune cells in the pancreas and overall size 
and composition.
In the clinic, it is common to test for the existence of diabetes-
associated autoantibodies, including GAD65, IAA, IA2, IGRP, 
and ZnT8 for diagnosis of patients with T1D (83, 84). It has been 
discussed that the titer and number of autoantibodies are a useful 
biomarker to predict disease progress in patients with T1D (84, 
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85). Currently, assays for measuring antigen-specific CD8 or 
CD4 T cells in both freshly isolated and cryopreserved peripheral 
blood mononuclear cells samples with flow cytometry-based 
HLA multimers are in progress and have been validated (84). 
Unfortunately, the percentage of autoantigen-specific T cells 
in the periphery is very low and often cannot be detected (84). 
Also, new barcoding with quantum dots has enhanced detection 
of autoreactive T cells but still require improvement (26, 84). In 
clinical trials, ELISpot is a common and widely used method 
to provide information about the functionality and quantity of 
immune cells (84–86). With ELISpot assays, we can measure 
cytokine responses to islet-specific antigens in T1D patients 
and healthy subjects (84). The number of cytokines that can be 
detected is increasing with improved fluorospot assays but still 
require development (84).
The failure for previous clinical trials may have not been only 
related to deficiencies in dosing and administration of tested 
therapies but also confounded by the late initiation of interven-
tion therapy in patients. As T1D development is more prevalent 
in children and their disease progression more aggressive than 
in adults, we may also consider the effect of age in conducting 
a successful intervention trial. Some therapies may be more 
effective in children than in adult patients (26). However, we still 
do not know the exact window of opportunity for treatment in 
humans, and the therapy has to first be tested and proven safe in 
adults before given to children. To achieve a successful and effec-
tive intervention study, we need a better strategy that includes 
stratification for study participants for future clinical trials.
Given the promising data of LD IL-2 in patients with HCV, 
GVHD, and Alopecia areata, there is great interest in giving LD 
IL-2 to patients with T1D to specifically boost Treg numbers and 
activity (15, 16, 62). This treatment can then be enhanced with 
an antigen-based therapy to increase the number and activity 
of Tregs in patients with T1D. In order to make progress with 
the application of LD IL-2 with an antigen-mediated therapy in 
clinical trials, it is required to develop robust immune biomarker 
assays to determine the extent of expansion of Tregs in quantity 
and quality that can help stratify patients, tell us whether a given 
therapeutic hit the right pathway. Most importantly, we must 
develop biomarkers that teach us about the natural history of the 
disease. These reliable immune biomarkers will enable optimal 
clinical study plans and enrollment of the proper cohorts of 
patients, regardless of age, that would benefit most from LD IL-2 
and antigen-based therapy. For more focus on biomarkers, please 
see Ryden et al. (77).
SUMMARY
In the present review, we discuss recent reports describing effi-
cacy and side effects with LD IL-2 treatment in preclinical and 
clinical experiments of select autoimmune diseases. A common 
theme emerges: there is a mild increase and expansion of Tregs 
observed in murine models as wells as in patients. However, a 
slight increase of NK cells has been reported in some clinical 
trials even using lower dose of Proleukin®. Our need for a better 
and safer dosing strategy of low dose of Proleukin® is required 
for efficient and safe use in T1D and other autoimmune diseases 
(Figure 2). Importantly, biomarkers are needed to determine the 
safe expansion of Tregs in quantity and quality. The goal of devel-
oping robust immune biomarkers will help us to stratify and treat 
the patients in whom we know LD IL-2 therapy will be efficacious 
(Figure 2). At the moment, the lack of robust and reproducible 
immune biomarkers is a bottleneck. Further effort will be needed 
to make the treatment of LD IL-2 safer and more efficacious.
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